Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9614.0600
Address
30 Flemington Road Bio21 Institute Parkville, Victoria (VIC) 3010
Description
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. It offers a diagnostic blood test for screening for colorectal cancer under the ColoSTAT brand. The company was founded on June 1, 2017, and is headquartered in Parkville, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.14
Trade Value (12mth)
AU$5,479.00
1 week
10.17%
1 month
4.84%
YTD
-25.29%
1 year
-5.8%
All time high
2.04
EPS 3 yr Growth
-13.80%
EBITDA Margin
N/A
Operating Cashflow
-$6m
Free Cash Flow Return
-179.80%
ROIC
-200.90%
Interest Coverage
-2,671.80
Quick Ratio
1.60
Shares on Issue (Fully Dilluted)
256m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
19 June 25 |
Overview of Genetype Presentation
×
Overview of Genetype Presentation |
11 June 25 |
Genetype Publication Market Update
×
Genetype Publication Market Update |
10 June 25 |
Change in substantial holding - Michelle Wing
×
Change in substantial holding - Michelle Wing |
02 June 25 |
Investor Presentation
×
Investor Presentation |
02 June 25 |
Application for quotation of securities - RHY
×
Application for quotation of securities - RHY |
02 June 25 |
Cleansing Notice
×
Cleansing Notice |
30 May 25 |
Proposed issue of securities - RHY
×
Proposed issue of securities - RHY |
26 May 25 |
ColoSTAT Beta kit verification and validation update
×
ColoSTAT Beta kit verification and validation update |
15 May 25 |
Breast Cancer Risk Study University of Melbourne
×
Breast Cancer Risk Study University of Melbourne |
02 May 25 |
Notification regarding unquoted securities - RHY
×
Notification regarding unquoted securities - RHY |
01 May 25 |
Proposed issue of securities - RHY
×
Proposed issue of securities - RHY |
24 April 25 |
Quarterly Activities Report and Appendix 4C 31 March 2025
×
Quarterly Activities Report and Appendix 4C 31 March 2025 |
14 April 25 |
RHY ISO13485 Recert Market Update
×
RHY ISO13485 Recert Market Update |
11 April 25 |
Application for quotation of securities - RHY
×
Application for quotation of securities - RHY |
08 April 25 |
Change in substantial holding
×
Change in substantial holding |
31 March 25 |
EGM - Investor Presentation
×
EGM - Investor Presentation |
31 March 25 |
RHY - Results of Meeting
×
RHY - Results of Meeting |
19 March 25 |
RHY Genetype Commercial Sales
×
RHY Genetype Commercial Sales |
18 March 25 |
Appointment of Chief Financial Officer
×
Appointment of Chief Financial Officer |
18 March 25 |
Notification regarding unquoted securities - RHY
×
Notification regarding unquoted securities - RHY |
17 March 25 |
Notification of cessation of securities - RHY
×
Notification of cessation of securities - RHY |
05 March 25 |
RHY Investor Webinar
×
RHY Investor Webinar |
27 February 25 |
Investor Webinar
×
Investor Webinar |
27 February 25 |
RHY - EGM Notice of Meeting and Proxy Form
×
RHY - EGM Notice of Meeting and Proxy Form |
21 February 25 |
Half-Year Financial Report and Appendix 4D
×
Half-Year Financial Report and Appendix 4D |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.